PubRank

Gilles Courtois

Author PubWeight™ 32.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003 6.11
2 TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002 3.21
3 Mature T cells depend on signaling through the IKK complex. Immunity 2003 2.21
4 NEMO trimerizes through its coiled-coil C-terminal domain. J Biol Chem 2002 1.41
5 Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappaB activation. Hum Mol Genet 2004 1.37
6 The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002 1.36
7 Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2005 1.34
8 Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines. J Biol Chem 2003 1.34
9 Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti. Hum Mol Genet 2007 1.25
10 Posttranslational modifications of NEMO and its partners in NF-kappaB signaling. Trends Cell Biol 2006 1.22
11 Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother. Pediatrics 2002 1.21
12 The trimerization domain of NEMO is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains. J Biol Chem 2004 1.11
13 Post-induction, stimulus-specific regulation of tumor necrosis factor mRNA expression. J Biol Chem 2007 1.05
14 NF-kappaB and inflammation in genetic disease. Biochem Pharmacol 2006 0.98
15 Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. J Biol Chem 2004 0.95
16 A point mutation in NEMO associated with anhidrotic ectodermal dysplasia with immunodeficiency pathology results in destabilization of the oligomer and reduces lipopolysaccharide- and tumor necrosis factor-mediated NF-kappa B activation. J Biol Chem 2005 0.95
17 Yersinia outer protein P suppresses TGF-beta-activated kinase-1 activity to impair innate immune signaling in Yersinia enterocolitica-infected cells. J Immunol 2005 0.95
18 Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res 2008 0.93
19 Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology. Hum Mol Genet 2010 0.90
20 "Without Ub I am nothing": NEMO as a multifunctional player in ubiquitin-mediated control of NF-kappaB activation. Cell Mol Life Sci 2010 0.87
21 Homozygosity mapping of a locus for a novel syndromic ichthyosis to chromosome 3q27-q28. J Invest Dermatol 2002 0.87
22 Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. Blood 2012 0.84
23 IKK-related genetic diseases: probing NF-κB functions in humans and other matters. Cell Mol Life Sci 2014 0.82
24 Erratum to: IKK-related genetic diseases: probing NF-κB functions in humans and other matters. Cell Mol Life Sci 2015 0.75
25 [New functions of NEMO, the regulatory subunit of IKK]. Med Sci (Paris) 2008 0.75
26 [CYLD deubiquitinase as a recurrent target in oncogenic processes]. Med Sci (Paris) 2011 0.75